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Summary
Objectives: To validate the World Health Organization (WHO) clinical staging and classification of
HIV/AIDS using CD4+ T-lymphocyte counts in the setting of a developing country.
Methods: This was a retrospective chart review of HIV-infected adults at the national HIV referral
clinic in the Kingdom of Saudi Arabia. Four hundred HIV-infected individuals were reviewed. All
individuals under the age of 15 years and those who had received antiretroviral therapy were
excluded.WHO clinical stage at presentationwas determined by a single reviewer. The first CD4+ T-
lymphocyte count within 6 months of diagnosis of HIV infection was then abstracted by a different
reviewer. Themain outcomemeasure was the comparison of theWHO clinical stages of HIV/AIDS at
the time of diagnosis and the CD4+ T-lymphocyte counts.
Results: Data were available for 191 individuals, of whom 123 were men and 68 were women. The
mean CD4+ T-lymphocyte count was 281/mm3 in the men and 425/mm3 in the women. The
distribution of individuals at theWHO clinical stageswas 110 at stage I, 10 at stage II, 36 at stage III,
and 35 at stage IV. Mean CD4+ T-lymphocyte counts were 457, 337, 188, and 86/mm3 at the
respective stages. The difference between the mean CD4+ T-lymphocyte count in patients at stage
IV and at each of the other stages was significant; p < 0.0001. The correlation between the stages
and the mean CD4+ T-lymphocyte counts was 0.65.
Conclusion: The WHO clinical staging and classification of HIV/AIDS correlates well with CD4+
T-lymphocyte counts.
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Since the early days of HIV infection and AIDS, it has been
recognized that the disease progresses in several stages due
to the progression of immunosuppression. The level of immu-
nosuppression is linked directly to the CD4+ T-lymphocytePublished by Elsevier Ltd. All rights reserved.
Table 1 p-Values in the comparison of mean CD4+ T-lympho-
cyte counts between the various World Health Organization
stages of HIV/AIDS
Stage (mean CD4+
T-lymphocyte count)
Stage I Stage II Stage III
IV (86/mm3) <0.0001 <0.0001 <0.001
III (188/mm3) <0.0001 0.01
II (337/mm3) 0.2
I (457/mm3)
244 J. Edathodu et al.count.1—5 Several organizations have classified and staged
HIV/AIDS infection. Classification and staging was first intro-
duced for the purpose of surveillance. The World Health
Organization (WHO) adopted a clinical staging system for
HIV/AIDS in 1990, emphasizing the use of clinical parameters
to guide clinical decision-making for the management of HIV-
infected individuals. This system was designed mainly for
use in developing countries and resource-limited settings,
where there is no access to laboratory services and where it is
not possible to assess the disease using CD4+ T-lymphocyte
counts.
The WHO clinical staging system has been widely used in
developing countries, especially in Africa. It has even been
used at the first level of referral in the local healthcare
systems. Other clinical disease classification systems, speci-
fically the one for North America from the Centers for Disease
Control and Prevention (CDC), are based on immunological,
clinical, and virological parameters that require laboratory
confirmation. Due to the importance of clinical classification
and staging of HIV/AIDS infections, the WHO has repeatedly
revised the staging system. For developing countries, in
particular the African regions, the Interim WHO clinical
staging of HIV/AIDS and HIV/AIDS case definitions for sur-
veillance was released in 2005.6 In that report the clinical
stages are clearly defined based on clinical diagnosis as
‘presumptive’ or as ‘definitive’ if more complex and sophis-
ticated laboratory tests are required. For practitioners, the
use of antiretroviral therapy and prophylactic treatment are
recommended based on the clinical stage of the patient at
presentation. To date, validation of the WHO clinical staging
and classification of HIV/AIDS using CD4+ T-lymphocyte
counts has not been reported.
Methods
Design and setting
The HIV/AIDS service at King Faisal Specialist Hospital and
Research Centre, Riyadh, Saudi Arabia, is the national HIV
referral center. It has accumulated rich data on the clinical
presentation of patients and their CD4+ T-lymphocyte
counts. The setting, being in a developing country, is the
first that we are aware of to validate the WHO clinical staging
using CD4+ T-lymphocyte counts.
Charts of all adult individuals aged 15 years and older,
confirmed to be HIV positive, were reviewed. All individuals
who had acquired the disease vertically were excluded.
Those who had been diagnosed and had been receiving
antiretroviral therapy before referral to our institution were
also excluded.
Basic demographic data were collected from charts. Each
individual chart was screened for documentation of any of
the clinical events listed in the WHO document at the time of
first presentation to our clinic. A single reviewer abstracted
these events (J.E.). The clinical stage was determined for
that particular individual. Individuals who had multiple signs
and symptoms were included into the most advanced stage
that they were in at the time of presentation.
The first measure of the CD4+ T-lymphocyte count within
three months prior to or after presentation to our institution
was then abstracted from the records by a different reviewer(B.A.) on a different occasion to eliminate the chance of bias.
Subsequently, all HIV-infected individuals were grouped
based on their WHO clinical stage: stage I, II, III, or IV.
Individuals at the same stage were grouped together and
their CD4+ T-lymphocyte counts were used for the analysis
and correlation testing.
Participants
Four hundred HIV-infected individuals were registered at the
HIV clinic. One hundred and ninety-one HIV-infected patients
met the inclusion criteria. HIV diagnosis was confirmed using
AxSYM1 HIV 1/2 gO MEIA (Abbott Laboratories, Abbott Park,
IL, USA). Positive sera were confirmed using Western Blot or
CHIRON1 RIBA1 HIV-1/HIV-2 SIA (Chiron Corp., Emeryville,
CA, USA). CD4+ T-lymphocyte counts were measured by
standard flow cytometry using FACSCaliburTM (Becton Dick-
inson, San Jose, CA, USA).
Statistical analysis
Statistical analysis was performed using Statistical Software
package version 5.0 (StatSoft, Tulsa, OK, USA). The Student’s
t-test was used to calculate continuous variables, and the
Chi-square or Fisher’s exact test was used for proportions. All
reported p values are two-tailed and a value of 0.05 was
considered significant.
Results
Data were available for 191 individuals, of whom 123 were
men and 68 were women. Men had more advanced disease in
this cohort. The mean CD4+ T-lymphocyte count was 281/
mm3 in men and 425/mm3 in women ( p < 0.001). At all
stages, men had lower mean CD4+ T-lymphocyte counts
compared to women. The mean age for men was 33 years
and for women 35 years.
The stage distribution of participants was 110 at stage I,
10 at stage II, 36 at stage III, and 35 at stage IV. The mean
CD4+ T-lymphocyte counts were 457, 337, 188, and 86/mm3
at the respective stages. Figure 1 depicts the CD4+ T-lym-
phocyte data for each stage. The difference in CD4+ T-
lymphocyte counts between stage IV and all other stages
was significant (Table 1). Only between stages I and II was the
difference not statistically significant.
Correlation testing revealed Spearman r = 0.65
(Figure 2). There were 16 out of 110 patients at stage I
(15%) with a CD4+ T-lymphocyte count of less than 200/
mm3; five of them had a CD4+ T-lymphocyte count of less
Figure 1 Box-and-whisker plot showing the median values and range of CD4+ T-lymphocyte counts at the different World Health
Organization stages of HIV/AIDS.
Figure 2 The correlation between the various World Health Organization stages of HIV/AIDS and CD4+ T-lymphocyte counts.
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between 100 and 197/mm3. On the other hand, of the five
out of 35 patients at stage IV (14%) with a CD4+ T-lymphocyte
count of more than 200/mm3, only one had a CD4+ T-lym-
phocyte count of more than 350/mm3. Other stages and
groupings of CD4+ T-lymphocyte counts are summarized in
Table 2.
Discussion
In our study we have shown that HIV clinical staging and
classification based on the recent WHO document6 doesTable 2 CD4+ T-lymphocyte counts in relation to World Health Or
CD4 <200/mm3 n (%)
Stage I (n = 110) 16 (15)
Stage II (n = 10) 3 (30)
Stage III (n = 36) 20 (56)
Stage IV (n = 35) 30 (86)correlate well with CD4+ T-lymphocyte counts, and thereby
with the level of immunosuppression. To our knowledge this
has not been previously reported. Teck et al. have reported
the CD4+ T-lymphocyte count of patients at stages III and IV in
relation to active or previous tuberculosis.7 They found that
nine out of 10 HIV-infected patients in Malawi presenting at
WHO stages III and IV with active or previous tuberculosis, had
a CD4+ T-lymphocyte count of less than 350/mm3. Similar to
our study, around 10—15% of patients at stages III and IV had
CD4+ T-lymphocyte counts above 350/mm3. Teck et al. only
looked at stages III and IV, whereas we looked at all stages.
Also, we have shown using Spearman r correlation testingganization stages of HIV/AIDS
CD4 200—350/mm3 n (%) CD4 >350/mm3 n (%)
29 (26) 65 (59)
3 (30) 4 (40)
10 (28) 6 (16)
4 (11) 1 (3)
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and CD4+ T-lymphocyte count at presentation. Kassa et al.
looked at CD4+ T-lymphocyte counts among patients at the
various WHO stages of 1993.8 In general, there was a good
correlation, but CD4+ T-lymphocyte counts were lower than
in our patients.
The difference in CD4+ T-lymphocyte counts between all
the WHO stages was significant except between stages I and
II. The staging tool was so sensitive that it had separated the
mean CD4+ T-lymphocyte counts between stages III and IV.
Therefore, it may be simpler to combine stages I and II. It is
reassuring to note that only 3% of patients at stage IV would
not need antiretroviral therapy if only CD4+ T-lymphocyte
count was used. In fact, it appears from our patients that the
WHO staging of HIV/AIDS would result in a slight under-
treating of patients rather than an over-treating. This is
especially suitable in resource-limited countries where the
availability of antiretroviral therapy is poor.
Another finding was the gender difference in CD4+ T-
lymphocyte counts at all stages. The mean CD4+ T-lympho-
cyte count in women was significantly higher than in men at
the same stage of the disease. We believe this is a pattern in
our HIV population related to the source of infection and
screening of partners.9
Ideally this study should have been undertaken in a pro-
spectivemanner, but this is not feasible in Saudi Arabia where
the number of new HIV infections per year is very low; it
would take several years to recruit a reasonable number of
individuals presenting at each of the different stages of the
disease into the study. Again for accurate clinical staging,
healthcare providers should have interviewed and examined
the individual with HIV infection, focusing on the symptoms,
signs, history, and laboratory findings specified in the WHO
document. This could be one of the reasons why we had more
patients at stage I as compared to stage II, as most of the
clinical signs at this latter stage are subtle, e.g., fungal
infection of nails, angular cheilitis, previous history of herpes
zoster, and recurrent upper respiratory infections, etc.
In spite of the above-mentioned limitations, this study
does prove that the WHO clinical staging of HIV/AIDS infec-
tion correlates well with the level of immunosuppression and
CD4+ T-lymphocyte counts, and will serve as a valuable toolto manage individuals with HIV infection in developing coun-
tries with limited resources, where themeasurement of CD4+
T-lymphocyte counts is not feasible.
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